A multicenter pilot study examining the role of circulating tumor cells as a blood-based tumor marker in patients with extensive small-cell lung cancer

Frontiers in Oncology

Volumn 4, Issue OCT, 2014, Pages

  Huang, Chao H ^a,b   Wick, Jo A ^c   Sittampalam, Gurusingham Sitta ^d   Nirmalanandhan, Victor Sanjit ^e   Ganti, Apar Kishor ^f   Neupane, Prakash C ^a   Williamson, Stephen K ^a   Godwin, Andrew K ^c   Schmitt, Sarah ^a   Smart, Nora J ^a   Spencer, Sarah ^b   Van Veldhuizen, Peter J ^a,b  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e PRINCESS MARGARET HOSPITAL   (Canada)

^f UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Biomarkers; Circulating tumor cells; Extensive stage; Prognosis; Small cell lung carcinoma

Indexed keywords

ETOPOSIDE; PLATINUM; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CELL PERMEABILIZATION; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; DECISION MAKING; DISEASE COURSE; EVALUATION AND FOLLOW UP; FEMALE; HUMAN; MALE; MIDDLE AGED; OVERALL SURVIVAL; PILOT STUDY; SMALL CELL LUNG CANCER; YOUNG ADULT;

EID: 84987958770     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00271     Document Type: Article

References (13)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin (2014) 64:9-29. doi:10.3322/caac.21208
2. Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol (2006) 24(28):4539-44.
3. Sundstrøm S, Bremnes RM, Kaasa S, Aasebø U, Hatlevoll R, Dahle R, et al. Cisplatin and etoposide regimen is superior to cyclyfophosphamide, epirubicin, and vincrisitine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow up. J Clin Oncol (2002) 20(24):4665-72. doi:10.1200/JCO.2002.12.111
4. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating tumor cells, disease progression and survival in metastatic breast cancer. N Engl J Med (2004) 351:781-91. doi:10.1056/NEJMoa040766
5. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol (2008) 26(19):3213-21. doi:10.1200/JCO.2007.15.8923
6. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, et al. Ciculationg tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res (2008) 14(19):6302-9. doi:10.1158/1078-0432.CCR-08-0872
7. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res (2004) 10:6897-904. doi:10.1158/1078-0432.CCR-04-0378
8. Momburg F, Moldenhauer G, Hammerling GJ, Moller P. Immunohistochemical study of the expression of a Mr 34, 000 human epithelium specific surface glycoprotein in normal and malignant tissues. Cancer Res (1987) 47:2883-91.
9. Kagan M, Howard D, Bendele T, Mayes J, Silvia J, Repollet M, et al. A sample preparation and analysis system for identification of circulating tumor cells. J Clin Ligand Assay (2002) 25(1):104-10.
10. Kagan M, Howard D, Bendele T, et al. Circulating tumor cells as cancer markers, a sample preparation and analysis system. In: Diamandis EP, Fritsche HA, Lilja H, Chan DW, Schwartz M, editors. Tumor Markers: Physiology, Pathobiology, Technology and Clinical Applications. Washington, DC: AACC Press (2002). p. 495-8.
11. Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol (2005) 23:1420-30. doi:10.1200/JCO.2005.08.140
12. Naito T, Tanaka F, Ono A, Yoneda K, Takahashi T, Murakami H, et al. Prognostic impact of circulating tumor cells in patients with small cell lung cancer. J Thorac Oncol (2012) 7(3):512-9. doi:10.1097/JTO.0b013e31823f125d
13. Hou JM, Krebs MG, Lancashire L, Sloane R, Backen A, Swain RK, et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol (2012) 30(5):525-32. doi:10.1200/JCO.2010.33.3716